Ovarian cancer clinical trials around the UK
Women with ovarian cancer told us how hard it was to find information about clinical trials taking place close to them, and that most who took part in our Pathfinder Study in 2009 had not been asked whether they would like to consider taking part in a clinical trial.
There are lots of things to consider when thinking about trials. We have some information currently on our site, with more to come very soon. Please do take a look. Unlike any other website in the UK, we now offer the facility to find out about trials in your local area, and where we have been given permission to publish it, information about how to contact the local team. It will be important to remember that you may or may not be allowed to join a trial, but it will provide a useful starting place for discussions with your clinician.
Just enter your postcode, and the distance you would be prepared to travel.
DNA Methylation single centre, Glasgow A non-randomised, single centre, sample collection trial of changes in ovarian tumour DNA methylation following chemotherapy at relapse.
Enumeration and Molecular Characterisation of Circulating Endothelial Cells (CECs) and Circulating Endothelial Progenitors (CEPs) in patients with Advanced Epithelial Ovarian and Endometrial Cancer Study of blood cells in patients with Advanced Epithelial Ovarian and Endometrial Cancer. In this study we would like to investigate the effect your chemotherapy has on these cells. This information will allow us to monitor the effectiveness of treatment in patients receiving chemotherapy or drugs which effect blood vessels.
DESKTOP III Approximately two thirds of patients treated with ovarian cancer will relapse within 12 months after completion of primary chemotherapy.The goal of this study is to evaluate whether a group of patients is selected using AGO scoring, benefit from the addition of surgery to their standard chemotherapy. To answer this question consenting patients will be randomly asigned to either the surgery with chemotherapy or chemotehrapy alone. The length of survival for both groups will be collected and analysed to see which treatment is better for these 'AGO positive' patients. This is an international trial that follows the protocol developed in Germany 408 aptients (204 in each group) will be randomised to experimental or control treatment in a 1:1 ratio over a period of 30 months. The UK is expected to recruit approximately 100 of the total patients.
Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? Higher Kingston Yeovil, Somerset The aim of this international prospective study is to find out the clinical benefits of palliative treatments and also to establish how treatments effect quality of life. The study is novel in giving equal attention to the patient’s perspective and the clinical response to treatment. The measures will help women make informed treatment decisions at a point in their illness where quality of life may be at least as important as survival time.
Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? London The aim of this international prospective study is to find out the clinical benefits of palliative treatments and also to establish how treatments effect quality of life. The study is novel in giving equal attention to the patient’s perspective and the clinical response to treatment. The measures will help women make informed treatment decisions at a point in their illness where quality of life may be at least as important as survival time.
